Galectin Therapeutics Inc (GALT.OQ)
Get access to over 18 million research reports from over 1,700 sources.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
- private equity
- third-party document and information retrieval
- and much, much more…
|62||2016||Chairman of the Board|
|48||2013||Chief Financial Officer|
|66||2014||Chief Operating Officer, Secretary|
|68||2000||Executive Vice President - Manufacturing and Product Development|
|45||2013||Executive Director - Regulatory Affairs and Quality Assurance|
- BRIEF-Galectin Therapeutics Says $10 Mln Credit Line From Richard Uihlein Sufficient To Cover Expected Expenditures Into 2019
- UPDATE 1-Galectin slumps after NASH drug misses main goal of mid-stage trial
- BRIEF-Galectin Therapeutics Announces Results From Phase 2b NASH-CX Trial Of GR-MD-02
- Galectin says NASH drug misses main goal of midstage trial
- BRIEF-Galectin Therapeutics To Present Results From Phase 2B Nash-Cx Trial On December 5, 2017